Introduction
============

Since the fight against cancer is far from being won, there is a need to think of new strategies to identify alternative targets for cancer diagnosis and combinatorial therapies. Current challenges include the desire to detect cancer much earlier, to prevent or reduce the emergence of acquired drug resistance [@b1], and to reduce the often lethal side effects. Even more challenging is the fact that different cancer cells from the same tumor can use different pathways to achieve drug resistance [@b2]. The complexity of pathways that can lead to drug resistance prevents to predict which treatment modality might finally allow the host rather the cancer to survive [@b3],[@b4]. Continued chemotherapy will target only a subset of cancer cells, while the resistant cells continue to grow [@b2]. New strategies are therefore needed to target nonresistant and resistant cancer cells. Protein phosphorylation is the key regulatory posttranslational modification exploited for intracellular signaling [@b5]--[@b7], and kinases require sufficiently high ATP levels to transfer a phosphate group. Today, it is believed that one third of human proteins are phosphorylated [@b8] and small-molecule kinase inhibitors have thus taken the lead as next generation cancer drugs (Table[1](#tbl1){ref-type="table"}) [@b9]. While this is a significant progress, these inhibitors often interfere with other complex intracellular signaling networks thus causing sometimes severe side effects, and need to be combined with other approaches.

###### 

Small-molecule kinase inhibitors on the market against kinases

  Name          Trade name          Targeted tyrosine kinase                                               Disease                                                                                                       Producer
  ------------- ------------------- ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ---------------------------------------
  Imatinib      Gleevec, Glivec     BCR-Abl                                                                Chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs), number of other malignancies     Novartis
  Gefitinib     Iressa              EGFR                                                                   Breast, lung, other cancers                                                                                   AstraZeneca, Teva
  Erlotinib     Tarceva             EGFR                                                                   Nonsmall cell lung cancer (NSCLC), pancreatic cancer, several other types of cancer                           Genentech, OSI Pharmaceuticals, Roche
  Crizotinib    Xalkori             ALK                                                                    Nonsmall cell lung cancer (NSCLC)                                                                             Pfizer
  Dasatinib     Sprycel             BCR/Abl and Src family                                                 Chronic myelogenous leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)   Bristol-Myers Squibb
  Lapatinib     Tykerb/Tyverb       HER2 and EGFR                                                          Breast cancer, other solid tumors                                                                             GlaxoSmithKline
  Nilotinib     Tasigna             BCR-ABL, KIT, LCK, EPHA3, EPHA8, DDR1, DDR2, PDGFRB, MAPK11, and ZAK   Chronic myelogenous leukemia                                                                                  Novartis
  Pazopanib     Votrient            c-KIT, FGFR, PDGFR, and VEGFR                                          Renal cell carcinoma, soft tissue sarcoma                                                                     GlaxoSmithKline
  Sunitinib     Sutent              PDGF-Rs, VEGFRs, KIT                                                   Renal cell carcinoma (RCC), gastrointestinal stromal tumor                                                    Pfizer
  Sorafenib     Nexavar             VEGFR, PDGFR, Raf                                                      Renal cell carcinoma (RCC), unresectable hepatocellular carcinomas (HCC), thyroid cancer                      Bayer, Onyx Pharmaceuticals
  Vandetanib    Caprelsa            VEGFR, EGFR, RET-tyrosine kinase                                       Tumors of the thyroid gland                                                                                   AstraZeneca
  Tofacitinib   Xeljanz, Jakvinus   JAK                                                                    Rheumatoid arthritis                                                                                          Pfizer
  Ruxolitinib   Jakafi, Jakavi      JAK                                                                    Myelofibrosis                                                                                                 Incyte Pharmaceuticals, Novartis

Current FDA-approved kinase inhibitors on the market in cancer treatment.

Cells secrete a cocktail of enzymes, such as cholinesterases, peptidases, transpeptidases, nucleotidases, phosphodiesterases, ectokinases, and ectophosphatases, which lead to posttranslational modifications of extracellular matrix (ECM) proteins, and the composition of this cocktail depends on cell type, external stimulations, and disease [@b10]. Posttranslational modifications of ECM proteins can affect outside-in cell signaling and consequently cell behavior [@b11]. The massive killing of cancer cells typically increases the local extracellular concentrations of the cytoplasmic content, including ATP, thereby causing additional posttranslational modifications of the ECM. The killing of cancer cells will thus leave behind a "diseased" ECM that can send altered instructive signals to the cells that later invade this cancerous ECM left behind. This has not been considered in the treatment of cancer previously.

Beyond using the concentration of extracellular protein kinases in blood to detect cancer in early stages [@b12]--[@b14], ectokinases and ectophosphatases might serve as new drug targets. Shielded by the plasma membrane, drugs with extracellular targets might cause less side effects as they can less directly interfere with intracellular signaling [@b15]--[@b21]. Even though cancer is not only a disease of cells but also leads to posttranslational modifications of the ECM, the *intra*cellular focus has overshadowed potential *extra*cellular opportunities that could be exploited to address some of these challenges. Here, we thus review the indications that cancer is not only a disease of cells but also of the ECM, and how this newly emerging knowledge of extracellular posttranslational modifications can potentially be exploited for cancer diagnosis and treatment.

Extracellular Enzymes and Posttranslational Modifications of ECM Coregulate Cancer Progression
==============================================================================================

Extracellular strategies are mostly missing although considerable knowledge emerged that the composition and rigidity of the ECM, and consequently ECM cell signaling plays an important role in cancer progression [@b22],[@b23]. The first wave of targeting ECM enzymes was motivated by the finding that cancer tissues show upregulated matrix metalloproteinase (MMP) levels, and it was thought that MMP-induced cleavage of ECM would promote the escape of cancer cells from the site of tumors [@b24],[@b25] (Fig.[1A](#fig01){ref-type="fig"}). Consequently, MMP inhibitors were designed and went into clinical trials, but with devastating negative outcomes [@b26],[@b27]. The main reason for the failure was the lack of appreciation for the complexity of MMP functions and their respective effects on ECM properties and signaling. Only three MMPs had been described at the time when the clinical trials had started, while 23 different MMPs are known today [@b28]. They were found in different cell types with diverse functions including ECM--cell interactions, cell--cell contact, and regulation of soluble factors among many others [@b27]. Broad-spectrum inhibitions of MMPs thus interfere with their diverse regulatory roles and thereby cause major side effects [@b29].

![Extracellular enzymes in cancer. (A) To alter the extracellular matrix (ECM) biology of cancer, matrix metalloproteinases (MMPs) served as first extracellular drug targets. The hypothesis was that matrix metalloproteinases (MMP) inhibition can prevent the local degradation of ECM and thus the escape of metastatic stroma cells. (B) Vesicle secretion and cell necrosis transiently releases intracellular content high in kinases and ATP into the surrounding tissue as indicated by the graded plume. For a short time period, the ATP levels are sufficiently high for the kinases to be active in extracellular space leaving behind phosphorylated ECM. Ectokinases and phosphatases thus provide unique opportunities as novel extracellular drug targets.](cam40004-0404-f1){#fig01}

It is thus timely to consider alternate extracellular strategies, including extracellular enzymes or other means by which to regulate posttranslational modifications (Fig.[1B](#fig01){ref-type="fig"}). While the importance of various posttranslational modifications in the ECM are known to regulate cancer progression [@b23], the significance of ectokinases and ectophosphatases, and the signatures they leave behind, is only now at the verge of being recognized [@b30]. Why should we even consider extracellular phosphorylation since the ATP levels are typically low in extracellular environment? Extracellular ATP can transiently increase to levels that are sufficiently high to activate ectokinases in those tissues that undergo major necrosis and apoptosis, thereby releasing intracellular content [@b30]. Also ATP secretion pathways are significantly upregulated in cancers [@b31],[@b32] and increased levels of extracellular ATP could recently been measured at tumor sites [@b33].

Among the reported *ecto*kinases, the most prominent ones are the casein kinase II (CKII) [@b34], protein kinase A (PKA) [@b35], protein kinase C (PKC) [@b36], and the recently reported Fam20C kinase [@b37]. Several ectophosphatases including alkaline phosphatase [@b38], tartrate-resistant acid phosphatase (TRAP) [@b39], and the most recently reported PTEN phosphatase [@b40] have been reported in the ECM. Interestingly, the concentration of the extracellular alkaline phosphatase is already measured routinely as a disease marker in patient\'s blood samples to detect liver diseases, bone disorders, or cancer and the TRAP is being discussed as a good candidate [@b39],[@b41].

Taken together, considerable evidence is emerging that posttranslational modifications of ECM coregulate cancer progression, that ectokinases and ectophosphatases are found in body fluids of cancer patients, and that kinases can be transiently active in extracellular space in regions where necrosis or other factors cause the release of ATP. As with any discovery, new ideas and strategies are thus beginning to emerge how to exploit these emerging insights into early cancer detection and therapy.

Striking Signatures of Extracellular Kinase Activity Are Found in Cancer Tissues
================================================================================

Postulating that massive necrosis might temporarily upregulate ectokinase activity in extracellular space, we recently mined published proteomic data and found a significant upregulation of phosphorylated residues in tissue samples from cancer patients [@b30]. This included the phosphorylation of ECM proteins, as well as of cell surface and extracellular domains of transmembrane proteins. Screening more than 60 different extracellular proteins revealed that nearly all can occur in phosphorylated states [@b30]. Most compelling was the finding that the integrin subunits *α*4 and *β*1, two key players in cancer progression and signaling, were found in tissue samples to be phosphorylated in their extracellular domains [@b30],[@b42]--[@b44]. Since fibronectin [@b45]--[@b47] which is a key component of the ECM is known to be highly upregulated in cancer [@b48]--[@b53], we further analyzed published proteomic data and found that fibronectin is indeed heavily phosphorylated in clinical cancer tissue samples (Fig.[2](#fig02){ref-type="fig"}, Table[2](#tbl2){ref-type="table"}). Heavily phosphorylated regions in fibronectin include and are associated with growth factor binding sites (FnIII~4~, FnIII~13-14~) and with domains that regulate fibronectin fibrillogenesis. This is an important finding since growth factor signaling and ECM fibrillogenesis are essential regulators in cancer malignancy and progression [@b22]. In addition to fibronectin, elevated levels of phosphorylated fibrinogen A are found in the plasma from patients with stage III or IV ovarian cancer compared to healthy controls [@b54].

![Experimentally verified phosphorylation sites on fibronectin. Schematic representation of plasma fibronectin with modules type I (gray), type II (turquoise), and type III (orange). (A) Locations of various bacterial and cell binding sites on the fibronectin monomer. (B) Experimentally identified phosphorylation sites by mass spectrometry techniques as retrieved from protein data banks Phosida, PhosphoSitePlus, PhosphoNet, HPRD, dbPTM, and UniProt for human Fn (P02751). (C) Locations of protein binding sites on the fibronectin monomer with a special focus on matrix metalloproteinases (MMPs).](cam40004-0404-f2){#fig02}

###### 

Experimentally verified phosphorylation sites on fibronectin in cancer samples

  Residue (P02751)                                                       Location/binding sites                                       Reference/databases                                                                         Cancer tissues/cells
  ---------------------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Y101, Y106, T136                                                       FnI2, Fn--Fn, Heparin, Tenascin, Fibrin                      PhosphositePlus, PhosphoNet                                                                 In seven patients samples (Y101): ovarian, liver, lung, esophageal, gastric
  In one patient sample (Y106): ovarian                                                                                                                                                                                           
  In one patient sample (T136): T-cell leukemia                                                                                                                                                                                   
  Y372                                                                   FnII1, Collagen, Gelatin                                     PhosphositePlus, PhosphoNet                                                                 In three patients samples: ovarian, liver, hepatocellular carcinoma, hepatocyte--liver
  Y588                                                                   FnI9, Collagen, Gelatin                                      PhosphositePlus, PhosphoNet                                                                 In one patients sample: lung carcinoma
  Y641                                                                   FnIII1, Fn--Fn                                               PhosphositePlus, PhosphoNet                                                                 In one patients sample: pancreatic carcinoma
  S904                                                                   Linker FnIII3--FnIII4                                        Phosida, PhosphositePlus, PhosphoNet, HPRD,dbPTM [@b79]                                     HeLaS3 (cervical cancer)
  S909                                                                   FnIII4, DNA binding                                          HPRD, dbPTM [@b80]                                                                          Hela cells
  Y937, T960, S968, T972                                                 FnIII4, DNA binding                                          PhosphositePlus, PhosphoNet                                                                 In one patients sample (Y037): gastric
  In one patients sample (T960): T-cell leukemia                                                                                                                                                                                  
  In one patients sample (S968): T-cell leukemia                                                                                                                                                                                  
  In one patients sample (T972): T-cell leukemia                                                                                                                                                                                  
  Y1042                                                                  FnIII5                                                       PhosphositePlus, PhosphoNet, dbPTM [@b81]                                                   Embryonic stem cells
  Y1206                                                                  FnIII7                                                       PhosphositePlus, PhosphoNet                                                                 In two patients samples: ovarian
  T1271                                                                  FnIII8, Cell binding region                                  PhosphositePlus, PhosphoNet                                                                 In one patients sample: colorectal
  T1462                                                                  FnIII10, Cell binding region                                 PhosphositePlus [@b82]                                                                      293 (epithelial)
  T1743, T1762, T1786, S1833, T1840, T1842, T1855, T1860, Y1879, Y1884   FnIII13, Heparin, Syndecan-4                                 PhosphositePlus, PhosphoNet                                                                 In one patients sample (T1743): T-cell leukemia
  In one patients sample (T1762): esophageal                                                                                                                                                                                      
  In one patients sample (T1786): esophageal                                                                                                                                                                                      
  In one patients sample (S1833): liver, cholangiocellular carcinoma                                                                                                                                                              
  In two patients samples (1840): cervical                                                                                                                                                                                        
  In one patients sample (T1842): cervical                                                                                                                                                                                        
  In two patients samples (T1855): cervical                                                                                                                                                                                       
  In one patients sample (T1860): cervical                                                                                                                                                                                        
  In one patients sample (Y1879): ovarian                                                                                                                                                                                         
  In two patients samples (Y1884): ovarian, T-cell leukemia                                                                                                                                                                       
  S2007                                                                  Variable region IIICS, LDV, REDV integrin binding sites      Phosida [@b83]                                                                              Hela cells
  S2131, S2139                                                           FnIII15, Cryptic cysteine                                    [@b84]                                                                                      U266 (immortal B lymphocytes derived from multiple myeloma)
  S2174                                                                  FnIII15, Cryptic cysteine                                    Phosida, [@b83],[@b85],[@b86]                                                               Hela cells, HEK, human liver tissue
  S2182, S2209                                                           FnIII15, Cryptic cysteine                                    Phosida [@b83]                                                                              Hela cells
  S2251                                                                  FnI10, Fibrin binding                                        [@b84]                                                                                      U266 (immortal B lymphocytes derived from multiple myeloma)
  Y2258                                                                  FnI11                                                        PhosphositePlus, PhosphoNet                                                                 In one patient sample: ovarian
  S2259, S2285, S2293                                                    FnI11, Fibrin binding, Protein-disulfide isomerase binding   [@b84]                                                                                      U266 (immortal B lymphocytes derived from multiple myeloma)
  S2294                                                                  FnI12, Fibrin binding, Protein-disulfide isomerase binding   Phosida, [@b83],[@b85],[@b86]                                                               Hela cells, HEK, human liver tissue
  S2318                                                                  FnI12, Fibrin binding, Protein-disulfide isomerase binding   dbPTM [@b84]                                                                                U266 (immortal B lymphocytes derived from multiple myeloma)
  S2328                                                                  FnI12, Fibrin binding, Protein-disulfide isomerase binding   Phosida, [@b83],[@b85],[@b86]                                                               Hela cells, HEK, Human liver tissue
  S2341, S2349                                                           C-terminus, Disulfide bonds for Fn assembly                  dbPTM, [@b84]                                                                               Serum
  Y2350                                                                  C-terminus, Disulfide bonds for Fn assembly                  PhosphositePlus, PhosphoNet                                                                 In two patients samples: breast, ovarian
  Y2353                                                                  C-terminus, Disulfide bonds for Fn assembly                  PhosphoNet, PhosphositePlus [@b87]                                                          In 12 patient samples, breast, lung, gastric, liver, hepatocellular carcinoma
  S2353                                                                  C-terminus, Disulfide bonds for Fn assembly                  Phosida, [@b83],[@b85],[@b86]                                                               Hela cells, HEK, human liver tissue
  S2354                                                                  C-terminus                                                   PhosphositePlus, PhosphoNet                                                                 In one patient sample: ovarian cancer
  S2376                                                                  C-terminus, Disulfide bonds for Fn assembly                  [@b84]                                                                                      U266 (immortal B lymphocytes derived from multiple myeloma)
  S2384                                                                  C-terminus, Disulfide bonds for Fn assembly                  Phosida, PhosphoSitePlus, PhosphoNet, dbPTM, UniProt, [@b83],[@b84],[@b86],[@b88]--[@b90]   In 14 patients samples: breast, skin, liver, hepatocellular carcinoma, and surrounding tissue, blood plasma U266 (immortal B lymphocytes derived from multiple myeloma), Hela cells
  S2419                                                                  C-terminus, Disulfide bonds for Fn assembly                  [@b83],[@b85],[@b86]                                                                        Hela cells, HEK, human liver tissue
  S2432, S2440                                                           C-terminus, Disulfide bonds for Fn assembly                  HPRD [@b84]                                                                                 U266 (immortal B lymphocytes derived from multiple myeloma)
  S2444                                                                  C-terminus, Disulfide bonds for Fn assembly                  Phosida [@b83]                                                                              Hela cells
  S2475                                                                  C-terminus, Disulfide bonds for Fn assembly                  HPRD [@b83],[@b85],[@b86]                                                                   Hela cells, U266 (immortal B lymphocytes derived from multiple myeloma)

Phosphorylated sites by mass spectrometry retrieved from protein databases. Due to lack of track changes and updates of the databases, the reported sites here may differ from the database entries at later points. Table as of Nov. 2014.

Taken together, available data suggest that the upregulated phosphorylation of fibronectin and of some other extracellular proteins is a distinct signature of cancerous ECM. The phosphorylation of the ECM caused by the transient release of ATP by dying cells might thus be physiologically far more important in regulating cancer cell differentiation and tumor progression than previously thought. Indeed, the phosphorylation ratio of peptides increase with tumor size as has been previously shown [@b13]. Any discovery of new signatures how cancer or cancer tissues are different from the norm might offer valuable entrance points for novel diagnostic or therapeutic strategies. Furthermore, extracellular proteins that are highly phosphorylated in some but not in other cancer types might be suitable as novel markers for the early detection of cancers, or perhaps serve as signature of its malignancy.

New Strategies for Cancer Diagnostics: Quantification of the Concentrations and Activities of Extracellular Protein Kinases
===========================================================================================================================

One major challenge is to detect cancer in earlier stages in order to treat patients more successfully. According to recent cancer statistics, the 5-year survival rate dramatically drops if cancer is detected at a late stage [@b55]. Most of the current serum tumor markers are based on the antigen determination method, including CEA, AFP, hCG, PSA, and CA125, but lack tumor specificity and often cannot be used in early cancer screening and diagnosis [@b56]--[@b63]. To overcome these shortcomings, novel, cheap, and fast diagnostic tools need to be developed. Measurements of ectokinase and ectophosphatase concentrations and activities in serum might thereby provide new opportunities (Fig.[3](#fig03){ref-type="fig"}). Such measurements could be embedded in routinely performed blood tests to screen for cancer long before patients show symptoms. Recent studies with more than 600 patients (374 healthy controls, 229 cancer patients) showed a significant upregulation of ecto-PKA concentrations in serum of cancer patients in contrast to healthy controls [@b64]. While more than 70% of the control patients had undetectable or low ecto-PKA concentrations in serum, more than 85% of the cancer patients had high levels of PKA concentrations, with average activity fivefold higher compared to the healthy controls. In another independent study, sera of 500 patients (295 various cancers, 155 normal controls, 55 without cancer) were analyzed by autoantibody against ecto-PKA. The presented anti-ecto-PKA measurement showed a 90% sensitivity and 80% specificity compared to the conventional methods with 83% sensitivity and 80% specificity [@b65]. Only recently, the quantification of ecto-PKA has been patented as a cancer marker for prostate and breast cancer [@b66]. As suggested by the research group, this approach has the potential to replace the commonly used PSA screening test for prostate cancer and the mammograms screening test for breast cancer, which cost nearly \$6 billion annually in the United States alone, with limited reliability of the outcome [@b67]--[@b69]. Alternatively or in combination, the ecto-PKC and ecto-CKII are other kinases well suited for phenotyping as they are reported in the ECM and show upregulated levels in secretory vesicles of prostate cancer samples [@b36],[@b70]. Such a path holds considerable promise particularly since a 10-fold increased abundance of ecto-PKC in serum of cancer patients with renal, colon, rectal, adrenal, and lung cancer compared to normal serum has recently been reported [@b71].

![From tumor sites to the blood stream: ectokinases and phosphatases as cancer markers. Enhanced ectokinase and ectophosphatase secretion is seen in intact tumor cells as well as from dying necrotic cells. Blood samples from cancer patients have significantly enhanced ectokinase and ectophosphatase concentrations and activities [@b64] and might thus serve as novel biomarkers. Several studies report higher selectivity and specificity of markers for early stage cancer detection.](cam40004-0404-f3){#fig03}

New Strategies for Cancer Treatment: Drug Targeting of Extracellular Protein Kinases and Phosphatases
=====================================================================================================

In the last two decades, intracellular protein kinases have emerged as the most important drug targets in pharmaceutical industry leading to some 20 approved drugs on the market and hundreds more in clinical trials [@b72]. To reduce side effects, a combinatorial approach is needed, one targeting and killing cancer cells while one also tries to prevent or revert the diseased state of ECM. One can further speculate that these drugs might have less side effects as they will not directly interfere with intracellular signaling events [@b73], but are expected to regulate primarily outside-in cell signaling. Since several important intracellular protein kinases and phosphatase including PKA, PKC, CKII, FAM20C, alkaline phosphatase, and PTEN phosphatase have been found as ectokinases and ectophosphatases, especially in cancer malignancy and progression [@b30], their potential as novel drug targets has been highlighted [@b74],[@b75], but not yet systematically exploited. The overexpression of ecto-PKA in secretory vesicles in prostate cancer further points to a putative regulatory role of ectokinases in cancer [@b70]. The expression of the ecto-PKA kinase, as probed in serum of melanoma patients, correlated with the appearance and size of the tumor and tumor removal reduced the levels of ecto-PKA [@b14]. Ecto-PKC is another kinase that has been reported to be present and active in sera of cancer patients with renal, colon, rectal, adrenal, and lung cancer [@b36],[@b71]. Both ecto-PKC and ecto-CKII have been reported to be expressed in secretory vesicles in prostate cancer and they might thus serve as novel targets [@b70]. The role for FAM20C kinase [@b37], which is present and active in the ECM, is already discussed in the regulation of bone metastasis [@b76].

Besides protein kinases, protein phosphatases could also serve as potential drug targets. Most recently, monoclonal antibodies were designed to target the extracellular alkaline phosphatase that is expressed on the surface of gastrointestinal cancer cells [@b77]. In addition, the PTEN phosphatase, a tumor suppressor that is known to induce tumor cell death in vitro and in vivo, has been reported to be secreted and subsequently enter other cells where it modifies their signaling and survival [@b40]. Finally, mutations in PTEN and their down regulation are reported to be involved in invasion and metastasis of colorectal carcinomas, indicating PTEN as a novel drug target and a marker for colorectal carcinoma [@b78]. Another advantage is that ectokinases and ectophosphatases could be targeted in cases where other drugs are not efficient anymore due to resistance of the tumor. Consequently, selected extracellular protein kinases and phosphatases might be good candidates for the development of novel drug targets.

Future Perspectives
===================

As extracellular protein phosphorylation is moving into the spotlight of attention, our goal here is to stimulate a thinking process how to best utilize this information for the fight of cancer. An increased understanding of the role of ectokinases and ectophosphatases in the regulation of outside-in signaling pathways in cancer malignancy and progression might result not only in exciting new science but also in the design of new combinatorial drugs that can display their functions in extracellular space [@b15]--[@b21], perhaps complementing conventional therapies, by modulating outside-in cell signaling through the posttranslational modification of extracellular proteins. Starting to apply the knowledge gained in the last 60 years about *intra*cellular protein kinases to the extracellular space offers new opportunities. Ultimately, we need to learn not only how to effectively kill cancer cells but also how to repair diseased cancerous ECM that is left behind and has the potency to send altered instructive signals to newly invading cells.
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